Profiling of Myositis Specific Antibodies and Composite Scores as an Aid in the Differential Diagnosis of Autoimmune Myopathies
Mahler, Michael (Research and Development, Inova Diagnostics, San Diego, CA 92131, USA; (K.M.); (A.S.); (C.B.))
Malyavantham, Kishore (Research and Development, Inova Diagnostics, San Diego, CA 92131, USA; (K.M.); (A.S.); (C.B.))
Seaman, Andrea (Research and Development, Inova Diagnostics, San Diego, CA 92131, USA; (K.M.); (A.S.); (C.B.))
Bentow, Chelsea (Research and Development, Inova Diagnostics, San Diego, CA 92131, USA; (K.M.); (A.S.); (C.B.))
Anunciación-Llunell, Ariadna (Hospital Universitari Vall d'Hebron)
Sanz-Martínez, María Teresa (Hospital Universitari Vall d'Hebron)
Viñas Gimenez, Laura (Hospital Universitari Vall d'Hebron)
Selva O'Callaghan, Albert (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia

Fecha:	2021
Resumen:	(1) Background: Myositis specific antibodies (MSA) represent important diagnostic and stratification tools in idiopathic inflammatory myositis (IIM) patients. Here we aimed to evaluate the clinical performance of MSA profiled by a novel particle based multi-analyte technology (PMAT) in IIM and subsets thereof. (2) Methods: 264 IIM patients and 200 controls were tested for MSA using PMAT (Inova Diagnostics, research use only). Diagnostic performance was analyzed and composite scores were generated. (3) Results: The sensitivity/specificity of the individual MSA were: 19. 7%/100% (Jo-1), 7. 2%/100. 0% (Mi-2), 3. 0%/99. 0% (NXP2), 3. 8%/100. 0% (SAE), 2. 7%/100. 0% (PL-7), 1. 9%/99. 5 (PL-12), 1. 1%/100. 0% (EJ), 15. 5%/99. 5% (TIF1γ), 8. 3%/98. 5% (MDA5), 6. 1%/99. 0% (HMGCR) and 1. 9%/98. 5% (SRP). Of all IIM patients, 180/264 tested positive for at least one of the MSAs. In the individual control group, 12/200 (6. 0%) tested positive for at least one MSA, most of which had levels close to the cut-off (except one SRP and one PL-12). Only 6/264 (2. 3%) IIM patients were positive for more than one antibody (MDA5/HMGCR, EJ/PL-7, 2 x MDA5/TIF1γ, EJ/SAE, SAE/TIF1γ). The overall sensitivity was 68. 2% paired with a specificity of 94. 0%, leading to an odds ratio of 33. 8. The composite scores showed good discrimination between subgroups (e. g. , anti-synthetase syndrome). (4) Conclusion: MSA, especially when combined in composite scores (here measured by PMAT), provide value in stratification of patients with IIM.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Myositis ; Autoantibodies ; Diagnosis ; Polymyositis ; Dermatomyositis ; Immunoassay
Publicado en:	Diagnostics, Vol. 11 (november 2021) , ISSN 2075-4418

DOI: 10.3390/diagnostics11122246
PMID: 34943483

14 p, 2.8 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados